Dr. Bennett is the executive vice president and chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance Ionis’ technology and expanding the company’s drug discovery platform. Dr. Bennett is also the franchise leader for gene-editing programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.
Dr. Bennett has been recognized for his research with numerous awards. He is a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research, the 2021 Gabbay Award and the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen), and the inaugural Healy Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS). Dr. Bennett also received the 2018 Hereditary Disease Foundation's (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington's disease (HD).
Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.
Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).
He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.
Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation and SAB for the McLaughlin Institute.
What is C. Frank Bennett's net worth?
The estimated net worth of C. Frank Bennett is at least $2.35 million as of December 20th, 2023. Dr. Bennett owns 65,754 shares of Ionis Pharmaceuticals stock worth more than $2,354,651 as of December 3rd. This net worth evaluation does not reflect any other assets that Dr. Bennett may own. Additionally, Dr. Bennett receives a salary of $651,640.00 as EVP at Ionis Pharmaceuticals. Learn More about C. Frank Bennett's net worth.
How old is C. Frank Bennett?
Dr. Bennett is currently 67 years old. There are 6 older executives and no younger executives at Ionis Pharmaceuticals. The oldest executive at Ionis Pharmaceuticals is Ms. B. Lynne Parshall Esq., J.D., Director, who is 70 years old. Learn More on C. Frank Bennett's age.
What is C. Frank Bennett's salary?
As the EVP of Ionis Pharmaceuticals, Inc., Dr. Bennett earns $651,640.00 per year. There are 5 executives that earn more than Dr. Bennett. The highest earning executive at Ionis Pharmaceuticals is Dr. Brett P. Monia Ph.D., Founder, CEO & Director, who commands a salary of $2,380,000.00 per year. Learn More on C. Frank Bennett's salary.
How do I contact C. Frank Bennett?
Has C. Frank Bennett been buying or selling shares of Ionis Pharmaceuticals?
C. Frank Bennett has not been actively trading shares of Ionis Pharmaceuticals within the last three months. Most recently, C Frank Bennett sold 6,500 shares of the business's stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $49.64, for a transaction totalling $322,660.00. Following the completion of the sale, the executive vice president now directly owns 65,754 shares of the company's stock, valued at $3,264,028.56. Learn More on C. Frank Bennett's trading history.
Who are Ionis Pharmaceuticals' active insiders?
Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?
During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company.
Learn More about insider trades at Ionis Pharmaceuticals. Information on this page was last updated on 11/12/2024.
